Real-World Use of First and Second Generation Tyrosine Kinase Inhibitors Pre- and Post-Hematopoietic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

2019 ◽  
Vol 19 ◽  
pp. S190
Author(s):  
Radhika Takiar ◽  
Anthony J. Perissinotti ◽  
Bernard L. Marini ◽  
Lydia Benitez-Colon ◽  
Patrick W. Burke ◽  
...  
Keyword(s):  
Stem Cell ◽  
Acute Lymphoblastic Leukemia ◽  
Hematopoietic Stem Cell Transplant ◽  
Kinase Inhibitors ◽  
Stem Cell Transplant ◽  
Lymphoblastic Leukemia ◽  
Philadelphia Chromosome ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
First And Second Generation

scholarly journals Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant

Hematology ◽  
2019 ◽  
Vol 2019 (1) ◽  
pp. 24-29 ◽  
Author(s):  
Adele K. Fielding
Keyword(s):  
Stem Cell ◽  
Acute Lymphoblastic Leukemia ◽  
Stem Cell Transplant ◽  
Kinase Inhibitor ◽  
De Novo ◽  
Lymphoblastic Leukemia ◽  
Philadelphia Chromosome ◽  
Cell Transplant ◽  
Older Individuals ◽  
Hematopoietic Stem

Abstract The understanding and treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia have changed rapidly in the past 10 years. The outcome is equally as good as for Ph− disease, and with targeted tyrosine kinase inhibitor therapies in addition to chemotherapy, the novel immunotherapy approaches, and the extension of allogeneic hematopoietic stem cell transplant (allo-HCT) to older individuals, there is the potential to exceed this outcome. There is particular interest in reducing chemotherapy exposure and considering for whom allo-HCT can be avoided. However, the patient population that can help test these options in clinical trials is limited in number, and the available evidence is often derived from single-arm studies. This paper summarizes outcomes achieved with recent approaches to de novo Ph+ acute lymphoblastic leukemia in the postimatinib era and helps integrate all the available information to assist the reader to make informed choices for patients in an increasingly complex field.

Sign in / Sign up

Export Citation Format

Share Document